# The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

> **NCT00001082** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 505 (actual)

## Conditions studied

- Cytomegalovirus Infections
- HIV Infections

## Interventions

- **DRUG:** Levocarnitine
- **DRUG:** Adefovir dipivoxil
- **DRUG:** Adefovir dipivoxil placebo

## Key facts

- **NCT ID:** NCT00001082
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-12
- **Primary completion:** 1999-01
- **Final completion:** 1999-08
- **Target enrollment:** 505 (ACTUAL)
- **Last updated:** 2013-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001082, "The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00001082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*